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The Priority Medicines (PRIME) scheme was launched by the European Medicines Agency 
(EMA) in 2016 to expedite the development and approval of promising products targeting 
conditions with high unmet medical need. Manufacturers of PRIME drugs receive extensive 
regulatory advice on their trial designs. Until June 2018, EMA granted PRIME status to 39 
agents, evaluated in 138 studies (102 initiated before and 36 after PRIME eligibility). A third of 
studies forming the basis of PRIME designation were RCTs and a quarter were blinded. There 
was no statistically significant difference between trials initiated before and after PRIME 
designation in terms of randomised design and use of blinding. However, significantly more 
efficacy studies included a clinical endpoint after PRIME designation than before, and 
significantly fewer included surrogate measures alone. There were no statistically significant 







Drug regulatory agencies are responsible for assessing the clinical efficacy and safety risks 
of novel therapeutic agents before they can be approved for use in clinical practice. In the 
European Union, pharmaceutical companies can market their novel products in all member 
states after receiving a single centralised authorization from the European Medicines Agency 
(EMA). EMA reviews data submitted by the manufacturer and grants a marketing authorisation 
for products that have a positive benefit-risk profile.  
Similar to other drug regulatory agencies such as the Food and Drug Administration 
(FDA) in the United States, EMA has sought to expedite the development and approval of new 
medicines.(1) In 2012, FDA introduced the breakthrough therapy designation to offer expedited 
development and review for drugs which intend to treat a serious or life threatening condition 
and indicate “substantial improvement over existing therapies” based on preliminary clinical 
evidence.(2) FDA’s breakthrough therapy designation effectively shortens the development 
timelines of eligible products.(3)   
In 2016, EMA launched the Priority Medicines (PRIME) scheme to parallel the FDA’s 
breakthrough therapy designation. The PRIME scheme is the latest regulatory pathway at the 
EMA’s disposal to expedite the development and approval of new medicines, including 
conditional marketing authorisations, accelerated assessments, and approvals under exceptional 
circumstances (Box 1).(4)   
According to the EMA, drugs are eligible for inclusion in its PRIME scheme if they have 
the potential “to offer a major therapeutic advantage over existing treatments, or benefit patients 
without treatment options”.(5) The scheme promises early dialogue on development plans and 
evidence requirements for approval between the EMA and manufacturers. PRIME allows 
manufacturers to receive extensive regulatory input on trial design by participating in EMA’s 
Scientific Advice program. Regulatory advice available to manufacturers also involves other 
stakeholders, including health technology assessment (HTA) bodies such as the National 
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Institute for Health and Care Excellence (NICE). Eligible products also benefit from the EMA’s 
accelerated assessment program, which further shortens regulatory review times (150 days with 
accelerated assessment versus 210 days for regular assessment).  
Novel therapeutic agents are eligible for the PRIME designation if they are at an early 
stage of development. Therefore, EMA makes a judgement about the potential therapeutic value 
of PRIME drugs on the basis of preliminary data. Given the extensive regulatory advice and 
input on the clinical testing and development activities of eligible drugs, trials of PRIME drugs 
would be expected to reflect regulatory and HTA preferences for study designs and endpoints, 
namely blinded randomised controlled trials that evaluate patient-centred outcomes.  
 In this study, we evaluate the evidence base on which the EMA determines PRIME 
eligibility of novel therapeutics. In addition, we describe the characteristics of clinical studies 
initiated before and after EMA’s PRIME designation. Finally, we compare the trial 
characteristics of drugs with and without PRIME designation in the same indication.  
 
Materials and methods  
Sample of drugs  
One researcher (EN) obtained the list of PRIME-designated products reported on the 
EMA’s website.(5) Because PRIME products are removed from this list upon application for a 
marketing authorisation, products which have applied or received a marketing authorisation were 
complemented from industry and regulatory press releases.(6) All products granted a PRIME 
designation before 1 June 2018 were included in the study sample, representing the first two 
years of the scheme.  
For each PRIME product, we characterised the substance type, therapeutic area, 
indication, and date of PRIME designation using publicly available information from the EMA’s 
webpage.(5) The manufacturer was identified through press releases related to the PRIME 
 5 
product. Products which received an orphan designation were identified from the European 
Commission’s ‘Register of Designated Orphan Medicinal Products’.(7) Whether any other therapies 
were approved in Europe for the same indication was determined by searching the EMA’s 
website. We also cross-checked whether PRIME products also received a breakthrough therapy 
designation from the FDA using sponsor press releases.  
 
Clinical studies of PRIME drugs 
EMA does not publicly release information about which studies formed the basis of 
PRIME designations. One researcher (EN) systematically catalogued and reviewed industry press 
releases to identify the clinical studies on which the PRIME eligibility was granted. The efficacy 
results for these studies were compiled from (in order of preference) peer-reviewed journal 
articles listed on clinicaltrials.gov, other peer-reviewed articles and published conference 
abstracts which included the trial NCT number, and industry press releases. 
For each PRIME product, one researcher (EN) then reviewed the clinicaltrials.gov 
registry to identify all clinical trials conducted (1) for the same indication as the PRIME 
indication, and (2) for which the industry sponsor was listed as a trial sponsor or collaborator. 
Clinicaltrials.gov is a National Institute of Health-maintained, publicly available online registry of 
clinical studies conducted across many diseases and conditions, and includes a database of study 
results.(8) Information on studies (e.g. study design, eligibility criteria, key dates) is submitted by 
trial sponsors and investigators. In cases where the product was acquired during the research and 
development process, we included both the studies conducted by the initial developer and the 





Data extraction from the identified clinical studies was performed by one researcher 
(EN) and checked for accuracy by a second (SAS). We first determined if the studies were 
randomised controlled trials (that is, if randomisation was used to allocate patients into different 
experimental and control groups). We then noted the study start and completion dates, study 
phase, comparator treatments, number of participants, and whether blinding was used to mask 
either participants, carers or investigators (or all) from treatment allocation.(9)  
We also extracted information on the primary and secondary endpoints of each clinical 
study. We then classified study endpoints into 5 categories: clinical efficacy, safety, 
pharmacodynamics, quality of life, and resource use. Efficacy endpoints were further classified as 
clinical, clinical scale, or surrogate measures, using a previously used classification.(10,11)  
The proportion of studies with randomised designs, active comparators, and blinding, as 
well as the average number of participants, were compared before and after the PRIME 
designation for each product. We also compared the proportion of studies reporting different 
types of endpoints before and after PRIME designation. 
 
Clinical studies of PRIME and non-PRIME drugs  
Characteristics of clinical studies of PRIME-designated drugs were compared to those of 
similar, “matched”, non-PRIME products. For each PRIME product with clinical studies 
available both before and after the PRIME designation, we identified all other products 
investigated for the same indication on clinicaltrials.gov. Non-PRIME drugs were eligible for 
inclusion in our comparator sample if they (1) had their first clinical study registered 
in clinicaltrials.gov during the same calendar year as those with PRIME designation, (2) had trials 
conducted both before and after the PRIME designation date, and (3) were not already 
authorised in Europe (i.e. not being studied for an extension of existing approved indication). 
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We extracted data on the design characteristics of clinical studies of eligible matched non-
PRIME drugs, as described above.  
 
Statistical analysis 
We used Fischer’s exact tests to characterise the features of clinical studies before and 
after PRIME designation and to compare the design features of PRIME and non-PRIME drugs 
(presence/absence of: randomisation, blinding, efficacy, quality of life or resource use endpoint, 
clinical outcome or surrogate measure). We used non-parametric Kruskall-Wallis test to compare 
the median numbers of participants between trials before and after PRIME designation, and 
between PRIME and non-PRIME products.  We repeated all analyses in a subgroup of late-stage 
trials (labelled as phase 2 or later on clinicaltrials.gov).   
 
Informed Consent and Ethics  




During the first two years of the scheme, the EMA granted PRIME designation to 39 
agents (table 1). Two agents (tisagenlecleucel for B-cell acute lymphoblastic leukaemia and 
axicabtagene ciloleucel for diffuse large B-cell lymphoma) received a marketing authorisation 
from the EMA in 2018.(12) Two other agents have applied for a regular and conditional 
marketing authorisation, respectively.(13,14) 14 products were included in the scheme in 2016, 
19 in 2017, and 6 in the first half of 2018. 23 (59%) products also have an FDA breakthrough 
therapy designation. Most products are being developed by larger companies (24/39, 61.5%). 
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PRIME drugs were mostly advanced therapies (medicines derived from genes, tissues, or 
cells (15)) (17/39, 43.6%), followed by small molecules (11/39, 28.2%), biologics (10/39, 
25.6%), and immunological agents (1/39, 2.6%). Approximately a third (12/39) targeted 
oncology indications. The majority of PRIME drugs had orphan designations (32/39, 82.1%) 
and a little over a half (21/39, 53.8%) targeted indications for which no EMA-approved 
treatments could be identified. 
 
Clinical studies supporting PRIME designation 
We were able to identify the most likely source of clinical data that supported the EMA’s 
PRIME designation for 26 drugs. Of these, 14 had a single clinical study available on 
clinicaltrials.gov. For the remaining 12, clinical studies could be identified from sponsor press 
releases. No information on the clinical studies forming the basis of PRIME designation was 
available in publicly available sources for the other 13 (33.3%) drugs.   
2 products were granted eligibility at the proof-of-principle stage. The 24 other drugs 
with data available were granted PRIME designation based on a total of 28 studies: 17 were 
phase 1 studies, and 11 were phase 2. Only 10 (36%) of these studies were RCTs with 7 placebo-
controlled and 3 active or standard-of-care controlled. 7 of these RCTs were blinded. Of the 24 
(86%) studies which included efficacy endpoints, 12 (50.0%) used a clinical endpoint and 10 
(41.7%) surrogate measures. Table 2 presents publicly available efficacy results from these 28 
studies (table S1).  
 
Characteristics of clinical studies before and after PRIME designation 
In total, we identified 148 studies conducted by an industry sponsor evaluating PRIME 
drugs in their relevant therapeutic indications. We excluded 9 extension studies and long-term 
follow-up studies, as well as 1 withdrawn study, from the subsequent analyses. Our analysis 
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therefore included 138 studies. As shown in figure 1, 102 clinical studies started before PRIME 
designation while 36 started after.  
 Table 3 presents the characteristics of clinical studies of drugs before and after PRIME 
designation. 41/102 (40.2%) of studies conducted before PRIME designation were RCTs, 
compared to 9/36 (25%) after (p = 0.112).  Of 102 studies conducted before PRIME eligibility, 
34 (33.3%) were blinded, compared to 7 out of 36 (19.4%) of those conducted after (p = 0.140). 
Median study enrolment was 50 (IQR: 23-128) participants in studies that started before PRIME 
designation and 56 (29-161) participants in studies that started after (p = 0.766).  
The proportion of studies including a quality of life endpoint was four times higher after 
PRIME designation than before (11/102, 10.8% vs 16/36, 44.4%; p < 0.001). Only two studies 
included any measure of resource use (frequency of hospital resource utilisation, number of 
intensive care unit inpatient days, and reason for hospital resource utilisation).  
Most clinical studies included at least one efficacy endpoint, both before and after 
PRIME designation. About a third of the studies included a clinical endpoint before PRIME 
designation, whereas over three fourths did after (33/87, 37.9% vs 26/33, 78.8%; p < 0.001). Of 
87 efficacy studies that started before PRIME designation, 35 (40.2%) only included surrogate 
measures as efficacy endpoints, compared to 3 of 33 (9.1%) that started after PRIME (p < 
0.001).  
 
Comparison to non-PRIME products 
 For the subset of PRIME drugs with matched non-PRIME drugs in the same indication 
and with clinical studies initiated in the same year, PRIME products were investigated in a total 
of 24 studies before the date of PRIME eligibility and 9 after. Non-PRIME products had a total 
of 18 studies before the PRIME eligibility date of their matched product and 8 after. 8/24 
(33.3%) of PRIME and 13/18 (68.4%) of non-PRIME studies were RCTs before eligibility 
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(p=0.028), and 3/9 (33.3%) and 4/8 (50%) after (p = 0.637), respectively (table 4). The use of 
blinding was less frequent among studies of PRIME products. 7/24 (29.2%) of PRIME and 
13/18 (72.2%) of non-PRIME trials were blinded before (p = 0.012), and 2/9 (22.2%) and 2/8 
(25%) after, respectively.  
While 9/20 (45.0%) of PRIME and 2/12 (16.7%) of non-PRIME efficacy trials included 
clinical outcomes before the designation was granted (p = 0.139), 7/9 (77.8%) and 4/5 (80%) 
included such outcomes after, respectively. About half of PRIME trials and three quarters of 
non-PRIME trials reported surrogate measures only before (11/20, 55% vs. 9/12, 75%; p = 
0.452), compared to about a fifth for both after PRIME eligibility (2/9, 22.2% vs. 1/5, 20%). 
 
Subgroup analysis: late-phase clinical studies 
Of the studies identified as phase 2 or later, more adopted randomised designs before 
than after PRIME eligibility (26/47, 55.3% vs. 9/30, 30%; p = 0.036), and more were blinded 
before than after PRIME eligibility (21/47, 44.7% vs. 7/30, 23.3%; p = 0.088) (table S2). Less 
than a quarter of the late-stage efficacy trials included a clinical endpoint before PRIME 
designation, whereas three-fourths did after (11/45, 24.4% vs. 23/30, 76.7%; p < 0.001). 
Respectively 15/45 (33.3%) and 1/30 (3.3%) of the late-stage trials included only surrogate 
measures before and after PRIME eligibility (p = 0.002). 
Median study enrolment was 81 participants (30-282) before PRIME designation and 70 
(36-196) after (p=0.863). Of note, phase 3 studies initiated after PRIME designation enrolled a 
median of 56 patients (34-241), enrolment varied with study design: the 7 RCTs in our sample 
included a median of 300 patients (128-520), while the 12 single-arm studies included a median 




In this systematic evaluation of the EMA’s PRIME scheme, we characterised the clinical 
studies of eligible products. The majority of drugs were granted PRIME designation based on 
non-randomised studies that measured surrogate markers alone. Studies initiated after PRIME 
designation were not more likely to have randomised designs and blinding but were more likely 
to include clinical endpoints. Median study enrolment was similar for studies initiated before and 
after PRIME designation. We did not observe any differences between these characteristics of 
clinical studies of PRIME and non-PRIME drugs.  
 
Evidence to support PRIME designation 
Consistent with existing guidance on PRIME applications,(16) the EMA relied mostly on 
exploratory data to judge the eligibility of products during the first 2 years of the scheme. For 
two products, PRIME designation was granted at the proof-of-principle stage. Entry at this very 
early stage is reserved to SMEs and applicants from the academic sector, in acknowledgement of 
the difficulty for smaller actors with limited knowledge of the regulatory processes to reach the 
proof-of-concept stage.(16) All other products with available information obtained PRIME 
designation following early clinical studies. Most of these studies were small single-arm trials, and 
nearly half included only surrogate measures. Findings of these studies were not routinely 
available in the published literature. When available, there was considerable variability in the 
completeness and method of reporting.  
While it was not possible to synthesize the findings of disparate studies measuring 
heterogeneous outcomes using different scales at various follow-up periods, important insights 
emerge. All products presented some indication of efficacy, ranging from dose-dependent 
slowing of disease progression to statistically significant increases in median overall survival. 
Within the third of the 21 studies with identified results which reported overall response rates as 
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the primary measurement of efficacy, the magnitude of the response rates varied greatly, from 
50% to 96%. Another third reported changes from baseline in clinical scale scores or surrogate 
outcomes. Survival-related benefits were mentioned for only 4 products; 2 products 
demonstrated statistically significant increases in median progression free survival (asunercept in 
glioblastoma, of 2 months and polatuzumab vedotin in relapsed and refractory diffuse large B 
cell lymphoma, of 4.7 months). A single product showed statistically significant gains in overall 
survival (polatuzumab vedotin, of 7 months). 
 
PRIME designation and trial design  
Evaluating the characteristics of studies initiated after EMA’s PRIME designation offers a 
glimpse of regulatory preference for trial designs. A similar proportion of studies that started 
after PRIME designation were blinded RCTs as compared to those that started before. Two 
thirds of the phase 3 studies initiated after the PRIME designation were single-arm studies 
including small numbers of patients (median: 37). We found that more studies initiated after 
PRIME designation included clinical outcomes rather than surrogate measures. In late-stage 
efficacy trials, less than 5% of studies included surrogate markers alone after PRIME eligibility, 
compared to a third before. Additionally, almost half of late-stage studies conducted after 
PRIME designation included quality of life endpoints, which are essential to ensure the validity 
of cost-effectiveness assessments conducted by HTA bodies.(17) The increased incorporation of 
quality of life endpoints in clinical studies may reflect scientific advice that includes HTA agency 
input.(18)  
We found no statistically significant difference in the design used and endpoints included 
in trials for PRIME and non-PRIME products. It is unclear how pharmaceutical manufacturers 
may interpret and act on the regulatory advice from EMA, and how the PRIME scheme fits into 
the broader landscape of regulatory pathways and programs at the EMA’s disposal.  
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Implications for regulatory and clinical practice 
The design and endpoints observed in studies after the PRIME designation likely reflect 
the influence of both the recent developments towards increased flexibility in granting marketing 
authorisations and the scheme itself. That PRIME designation is not associated with greater use 
of trial designs preferred by regulatory agency and HTA bodies, namely blinded RCTs, may 
reflect the larger trend of non-randomised and uncontrolled evaluations of drugs becoming 
increasingly common.(19)  Many therapies that receive the PRIME designation target relatively 
small populations. Also, reliance on studies with small sample sizes after the PRIME designation 
may indicate growing regulatory confidence in learning from even the smallest numbers of 
patients. PRIME studies fit within this regulatory landscape, which is evolving towards adaptive 
pathways, and appear consistent with EMA’s rethinking of evidence generation over medicines’ 
life-cycle.(20) 
The picture of PRIME medicines’ evidence base that arises from our analysis also 
underline the importance of post-approval confirmatory studies. Single-arm trials suffer from a 
range of biases, such as regression to the mean, patient selection effects, or variability in 
historical controls, as well as from confounding.(21) Although using surrogate measures has 
several advantages such as shortening the duration, size and complexity of trials, they also have 
disadvantages: treatment effects were on average 47% higher in trials measuring surrogate 
markers than in trials using patient-relevant outcomes, according to large meta-epidemiological 
studies.(22,23) As treatments effects shown in early phase studies often fail to be confirmed in 
later, more robust trials (24–27), there is a need to continuously monitor the therapeutic 
performance of products labelled as “priority medicines” on the basis of preliminary data.  
Taken together, our findings suggest that rigorous post-marketing studies should be conducted 
on PRIME-designated products, and in a timely manner. Currently, most post marketing studies 
are completed with significant delays.(28) 
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Our findings are important to inform clinicians and patients about the quantity and 
quality of data that supports new medicines. Patients and clinicians generally overestimate the 
benefits and underestimate the harms associated with new treatments approved by regulatory 
agencies.(29,30) In addition, they tend to overrate the level of evidence and efficacy indicated by 
the “breakthrough” and “promising” terminologies, as shown by recent research from the 
US.(31,32)   
Limitations 
The results of this study should be interpreted in light of its limitations. First, our 
evaluation is circumscribed by the information made available by the EMA. For example, the 
EMA does not disclose its rationale for granting PRIME designation at the product-level, and we 
were unable to identify the evidence base that supported 13 products based on publicly available 
information. Similarly, products which were denied PRIME eligibility and the reasons for denial 
could not be identified, curtailing our ability to compare the research and development trajectory 
of successful and unsuccessful PRIME applicants. The content of the extensive scientific advice 
received by manufacturers from the EMA is also not publicly available, preventing the appraisal 
of the extent to which observed differences in trial endpoints and characteristics before and after 
PRIME designation are attributable to participation in the scheme. This limitation could be 
addressed by the EMA by increasing transparency around regulatory processes and decisions. 
Second, our sample was small, as the scheme is relatively new. Nevertheless, our study 
constitutes the first systematic evaluation of the PRIME scheme. Third, our categorisation of 
trials as before or after PRIME designation, as well as the analysis of their characteristics and 
endpoints, depends on the accuracy of information available from company press releases and 
public trial registries. Fourth, trial designs conducted before and after the PRIME designation 
were at different stages of clinical development and may simply reflect the trajectory of clinical 
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development. We addressed this limitation by identifying a comparable set of products without 
the PRIME designation within the same therapeutic area.  
 
Future research directions 
A recent study in the US demonstrated that drugs that benefited from the FDA’s 
breakthrough therapy designation had shorter clinical development times.(3) However, a 
systematic review of breakthrough-designated oncology drugs showed that “there was no 
evidence that these drugs provide improvements in safety or novelty; nor was there a statistically 
significant efficacy advantage when compared with non–breakthrough-designated drugs”.(33) 
Whether drugs that benefit from the EMA’s PRIME scheme outperform non-PRIME-
designation products should be evaluated.  
Future research should thus scrutinize whether the PRIME scheme is meeting its 
primary objective of identifying and expediting the development and approval of transformative 
medicines in Europe. This entails evaluating both the safety and efficacy improvements brought 
by PRIME medicines, and the speed at which these medicines become available to patients. 
Whether the clinical benefits delivered by PRIME medicines and gains in time to patient access 
are aligned with the regulatory and economic advantages provided by the scheme should be 
assessed. Rigorously evaluating the safety and efficacy of novel therapies becomes even more 
crucial when they reach the patients faster. 
 
Conclusion 
EMA’s PRIME scheme aims to facilitate faster development and approval of promising 
medicines, as part of a broader effort to ensure early patient access to medicines that fulfil a high 
unmet need. In its first 2 years, PRIME eligibility was granted based on early clinical studies, 
which largely incorporated uncontrolled, non-randomised designs, and surrogate markers. There 
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was no difference in the proportion of trials which were controlled or blinded before or after 
eligibility, though numerically fewer trials adopted a robust design after. On the other hand, 
significantly more trials included clinical endpoints to measure efficacy or quality of life 
outcomes after PRIME eligibility. Overall, studies that were initiated before and after PRIME 
designation had similar sample sizes. There was no statistically significant difference between 
PRIME and non-PRIME drugs. Future research should examine if the scheme can effectively 






Study Highlights  
What is the current knowledge on the topic? 
 EMA recently introduced the Priority Medicines (PRIME) scheme to provide early and 
extensive regulatory input on drug development plans of selected promising drugs. 
 Drugs are eligible for inclusion if they have the potential to target an important unmet 
medical need. 
What question does this study address? 
 What is the evidence base on which EMA determines PRIME eligibility? 
 What are the characteristics of studies initiated before and after PRIME designation? 
  Do the trials for PRIME drugs differ from those of comparable products without 
PRIME designation? 
What does this study add to our knowledge? 
 EMA relied primarily on nonrandomised study designs with surrogate measures to 
determine the eligibility of drugs.  
 For eligible drugs, PRIME designation was not associated with the use of clinical 
endpoints and quality of life outcomes.  
 Clinical evidence generated on PRIME products was not significantly different from that 
on comparable non-PRIME products.  
How this might change clinical pharmacology or translational science? 
 Future translational research should evaluate both the comparative safety and efficacy of 
PRIME medicines, and the speed with which they reach the European market. 
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Figure 1: Timeline of clinical studies evaluating PRIME drugs  
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Box 1: Overview of EMA’s schemes aimed at expediting regulatory approval 
  
Regulatory pathway Primary objective  
Accelerated 
assessment(34) 
Aims at reducing the time from regulatory application to approval for products of 




Gives a path to market for medicines that could never meet the standard evidence 
requirements on risk-benefit profile because of the rarity of the disease, the present 
state of scientific knowledge, or the inability to collect safety or efficacy information 




Allows to give patient access to medicines with a likely positive risk-benefit profile 
before all the data normally required for authorisation is available, when the medicine 
has the potential to fulfil an important unmet medical need 
Priority Medicines 
(PRIME)(5) 
Aims at shortening the time to market for medicines that have the potential of 
delivering “a major therapeutic advantage over existing treatments” or addressing an 
unmet medical need by better matching development plans with regulatory evidence 
requirements and shortening the regulatory evaluation   
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Table 1: Characteristics of PRIME drugs 
Name 























No approved treatment  
Supportive care  














No approved treatment 








































No approved treatment 








Treatment of adult 
patients with relapsed or 




Approved treatments  








Treatment of adult 
patients with diffuse 
large B-cell 
lymphoma (DLBCL) 
who have not responded 
to their prior therapy, or 
have had disease 
progression after 











Treatment of relapsed 
and refractory multiple 
myeloma patients whose 
prior therapy included a 
proteasome inhibitor, an 
immunomodulatory 




No approved treatment 
in 4L 

















No approved treatment  
Supportive care 







types I, III and IV 
(Other) 
27/06/2016 














for depression, no 







Treatment of Patients 
with ANCA-Associated 
Vasculitis 




















No approved treatment 
Supportive care  





Treatment of NTRK 
fusion-positive, locally 
advanced or metastatic 
solid tumours in adult 
and paediatric patients 
who have either 
progressed following 
prior therapies or who 




Existing treatments but 
no other TRK 






Prevention of acute 






Approved treatment  





Treatment of relapsed 
and refractory multiple 
myeloma patients whose 
prior therapy included a 
16/10/2017 




proteasome inhibitor, an 
immunomodulatory 










Prevention of graft 










Treatment  of 
relapsed/refractory 




Approved treatments  





Treatment of septic 
shock 
(Infectious Diseases) 





Treatment of Primary 
Hyperoxaluria Type 1 
(Uro-nephrology) 
21/03/2016 
No approved treatment  











No existing vaccine to 
prevent or medicine to 
treat  





Treatment of chronic 
hepatitis D infection 
(Infectious Diseases) 





















or HLA-A*0206 allele 
positive patients with 
inoperable or metastatic 
synovial sarcoma who 
have received prior 
chemotherapy and 
whose tumour expresses 
the NY-ESO-1 tumour 
antigen 
(Oncology) 
21/03/2016 Approved treatments Yes 
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Treatment of paediatric 
patients diagnosed with 




No approved treatment 






Treatment of relapsed 
and refractory patients 




Approved treatments  










































Disorder in the 
allogeneic hematopoietic 
cell transplant setting 
who have failed on 
rituximab. 






Treatment of recurrent 
glioblastoma in patients 
for which a gross total 
resection is not possible 
or advisable, or for 




Approved treatments  










Treatment of paediatric 
patients with relapsed or 





Approved treatments  







Ebola (Zaire strain) 
(Vaccines) 


















Treatment of high grade 
glioma 
(Oncology) 












Curative HSCT   
Yes  
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Table 2: Efficacy data supporting PRIME designation  
Name 




Magnitude of effects forming the basis of PRIME designation 
A4250 
Chemical 






Designation granted based on pre-clinical data only 




Adjusted change from baseline on the Clinical Dementia Rating—Sum 
of Boxes (CDR-SB): demonstrated dose-dependent slowing of clinical 
progression with aducanumab treatment at one year (dose-response, 
P < 0.05) 
Composite neuropsychological test battery and Free and Cued Selective 
Reminding Test free recall: no changes from baseline at one year but 





Annualized FIX use: reduced by 81% from baseline  
Mean Annualized Spontaneous Bleeding Rate (ASBR): decreased from 




PFS-6 rates: 3.8% (95%-CI: 0.1 - 19.6) in the reirradiation group (rRT), 
20.7% (95%-CI: 11.2 - 33.4) in the rRT+APG101 group (p=0.04) 
Median PFS: 2.5 (95%-CI: 2.3-3.8) months and 4.5 (95%-CI: 3.7-5.4) 
months, HR = 0.49 (95% CI: 0.27-0.88, p=0.0162) 
Cox regression analysis adjusted for tumour size for death of any cause: 





Children's Hospital of Philadelphia Infant Test of Neuromuscular 

















With a median follow-up of 15.4 months, 42% of the patients continued 
to have a response, with 40% continuing to have a complete response. 
Higher CAR T-cell levels in blood associated with response. 





- No efficacy results identified 
bb2121 
Advanced therapy 
21 ORR = 89% 
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Brexanolone   
Chemical 
21 
Mean reduction in Hamilton Rating Scale for Depression (HAM-D) total 
score at 60 h from baseline: 21.0 points (SE 2.9) in the SAGE-547 group, 
8.8 points (SE 2.8) in the placebo group (difference -12·2, 95% CI -
20·77 to -3·67; p=0·0075; effect size 1.2)  
Dialnubicel  
Advanced therapy 
Not reported  
“The results of this study demonstrated that infusion of dilanubicel 
[NLA101] was safe and led to faster neutrophil and platelet recovery 





(Results from integrated analysis of pivotal phase II STARTRK-2, phase 
I STARTRK-1 and phase I ALKA trials; PRIME designation based 
mostly on STARTRK-2) 
ORR: 77.4% in non-small cell lung cancer  
DoR: 24.6 months. 




Results pertaining to Cohort 1 (N=4, 2.5 mg/kg given once-quarterly) 
“Meaningful reductions in the number and frequency of porphyria 
attacks”   
Mean decrease in the annualized attack rate compared with the run-in 
phase: 74%  
Mean reduction in annualized hemin administration: 75% 
Maximum attack-free interval (i.e., greatest period of time between 














ORR (reduction or elimination of donor-specific antibodies permitting 




ORR: 86% (38/44) 
CRR: 59% (26/44) 
3-month ORR: 66% (21/32),  
3-month CRR: 50% (16/32) 





Designation granted based on pre-clinical data only 







 >50% decreases in urinary oxalate excretion relative to baseline: all 
patients  









ORR: 50% (1 CR; 5 PR)  
Time to response: 6 wk (range 4-9)  
Median DoR: 31 wk (range 13-72). 





EFS: all 15 patients alive and event-free at 20 months of age, as 
compared with a rate of survival of 8% in a historical cohort 
CHOP INTEND score: rapid increase from baseline followed gene 
delivery in the high-dose cohort, with an increase of 9.8 points at 1 
month and 15.4 points at 3 months, as compared with a decline in this 





CR: 40 for Polatuzumab (Pola) + Bendamustine and Rituximab (BR) vs 
15 for BR alone (p = 0.012)  
Median PFS: 6.7mo (4.9; 11.1) for Pola+BR vs 2mo (1.5;3.7) for BR 
alone (p < 0.0001)  




12 in placebo 
group, 13 in 
seladelpar 50 
mg group, 10 
in seladelpar 
200 mg group 
Mean changes from baseline in alkaline phosphatase: -2% (SD 16) in 
placebo group, -53% (14) in seladelpar 50 mg group, -63% (8) in 
seladelpar 200 mg group (p<0·0001 for both groups vs placebo, 




Mean annualized bleeding rate: 11.1 events per year [range: 0 to 48] 
before vector administration vs. 0.4 events per year [range, 0 to 4] after 
administration (p = 0.02) 
Mean factor dose: 2908 IU per kilogram [range, 0 to 8090] before vector 
administration vs. 49.3 IU per kilogram [range, 0 to 376] after 
administration (p = 0.004) 
No use of factor: 8 of 10 participants  









Median annualized bleeding rate: decreased from 16 events before the 
study to 1 event after gene transfer among participants who had 
previously received prophylactic therapy 
Factor VIII use: ceased in all the participants in this cohort by week 22  
Sustained normalization of factor VIII activity level over a period of 1 
year: achieved in six of seven participants who received a high dose 
Stabilization of hemostasis: all 
Reduction in factor VIII use: all, deemed “profound”  
Voxelotor  
Chemical 




mg/day: N = 
38; Cohort 2, 





 “All patients who received multiple doses of voxelotor for ≥28 days 
experienced hematologic improvements including increased 
haemoglobin and reduction in haemolysis and percent of sickled red 
cells”  
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CI: Confidence Interval; CRR: Complete Response Rate; DoR: Duration of Response; EFS: Event Free Survival; HR: Hazard 
Ratio; ORR: Overall Response Rate; OS: Overall Survival; PFS: Progression Free Survival; PR: Partial Response 
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Table 3: Comparison of trial design and endpoints before and after PRIME-eligibility  
 



















   
  
      
  
All  
(n = 102) 























































   
  
      
  



























Late-stage trials  



























Number of trials (proportion), [95% confidence interval]; For the sample size, the interquartile range is reported 
Note: Long-term follow-up studies excluded; *Proportion of trials including an efficacy endpoint  
PK/PD: Pharmacokinetics/ pharmacodynamics; QoL: quality of life; SoC: standard of care   
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Table 4: Comparison of trial design and endpoints for products with and without PRIME designation 
 

















    
 
      
  




(n = 18) 
13 (72.2) 13 (72.2) 0 (0) 13 (72.2) 17 (94.4) 6 (33.3) 12 (66.7) 2 (11.1) 0 (0) 2 (16.7) 1 (8.3) 11 (91.7) 
326  
[64-500] 
p 0.028 0.012 >1 0.012 >1 0.343 0.147 0.573 >1 0.075 >1 >1 0.094 
AFTER 
    
 
      
  




(n = 8) 
4 (50) 2 (25) 2 (25) 2 (25) 7 (87.5) 6 (75) 5 (62.5) 1 (12.5) 0 (0) 4 (80) 0 (0) 2 (40) 
58 
[22-89] 
p 0.637 >1 0.576 >1 0.576 0.015 0.082 0.576 >1 >1 0.258 0.027 0.140 
Number of trials (proportion); For the sample size, the interquartile range is reported 
Note: Long-term follow-up studies excluded; *Proportion of trials including an efficacy endpoint  
















































Time to/from PRIME designation (days)
